Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyorin Pharmaceutical CoTSE:4569 +0.81%74 Debt-to-EBITDA is 1.63 as of Mar. 2026, which is 13% below its 10-year median of 1.88. GuruFocus rates TSE:4569 with a GF Score™ of 74/100 and a GF Value™ of 円1,580.21 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 681 Drug Manufacturers companies, Kyorin Pharmaceutical Co ranks worse than 67.84% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Kyorin Pharmaceutical Co's Debt-to-EBITDA or its related term are showing as below:
TSE:4569'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.41 Med: 1.88 Max: 2.97
Current: 2.97
During the past 13 years, the highest Debt-to-EBITDA Ratio of Kyorin Pharmaceutical Co was 2.97. The lowest was 0.41. And the median was 1.88.
TSE:4569's Debt-to-EBITDA is ranked worse than 67.84% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs TSE:4569: 2.97
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Kyorin Pharmaceutical Co Debt-to-EBITDA Related Terms
Kyorin Pharmaceutical Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyorin Pharmaceutical Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kyorin Pharmaceutical Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Kyorin Pharmaceutical Co (TSE:4569) has a Debt-to-EBITDA of 1.63 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Kyorin Pharmaceutical Co. This is 13% below median its historical median of 1.88. Over the past decade, Kyorin Pharmaceutical Co's Debt-to-EBITDA has ranged from 0.41 to 2.97. According to the industry distribution chart, Kyorin Pharmaceutical Co ranks #462 out of 681 companies in the Drug Manufacturers industry, placing it in the top 67.8%.
Is Kyorin Pharmaceutical Co's Debt-to-EBITDA too high?
Kyorin Pharmaceutical Co's current Debt-to-EBITDA of 1.63 is 13% below median its 10-year median of 1.88. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 2.97. The Drug Manufacturers industry median Debt-to-EBITDA is 1.63. Kyorin Pharmaceutical Co's value of 1.63 is 0% at this industry median. Based on the distribution chart, Kyorin Pharmaceutical Co ranks #462 out of 681 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Kyorin Pharmaceutical Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyorin Pharmaceutical Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kyorin Pharmaceutical Co ranks #462 out of 681 companies for Debt-to-EBITDA. This places Kyorin Pharmaceutical Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. Kyorin Pharmaceutical Co's value of 1.63 is 0% at this benchmark. Historically, Kyorin Pharmaceutical Co's own Debt-to-EBITDA has ranged from 0.41 to 2.97 over the past decade. While the company's 10-year median is 1.88 vs. the industry median of 1.63, Kyorin Pharmaceutical Co has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyorin Pharmaceutical Co's current Debt-to-EBITDA of 1.63 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Kyorin Pharmaceutical Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyorin Pharmaceutical Co's current Debt-to-EBITDA is 1.63, which is 13% below median its own 10-year median of 1.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyorin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co (TSE:4569) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,580.21, compared to a current price of 円1,118.00 — trading 29.2% below its estimated fair value. The current Debt-to-EBITDA is 1.63, which is 13% below median its 10-year median of 1.88 and 0% at the Drug Manufacturers industry median of 1.63. Kyorin Pharmaceutical Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Kyorin Pharmaceutical Co (TSE:4569), the current Debt-to-EBITDA is 1.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyorin Pharmaceutical Co (TSE:4569) Overvalued in 2026?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円1,118.00 is trading 29.2% below its estimated GF Value™ of 円1,580.21.
GuruFocus considers Kyorin Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4569:
Debt-to-EBITDA: 1.63 (13% below median its 10-year median of 1.88)
GF Value™: 円1,580.21 vs. price of 円1,118.00 (29.2% below fair value)
Industry Position: 0% at the Drug Manufacturers median (#462 of 681)
No single metric tells the full story. See the TSE:4569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
74GF Score
Get the complete analysis for TSE:4569
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4569 has been successfully added to your 
